索拉非尼治疗转移性肾癌的不良反应

doi:10.3971/j.issn.1000-8578.2010.05.027

索拉非尼治疗转移性肾癌的不良反应

Safety andManagement ofSorafenib inTreatment of 31 Patients with Metastatic Renal CellCarcinoma

摘要

摘要: 目的回顾分析31例使用靶向治疗药物索拉非尼治疗转移性肾癌患者的临床资料，评价索拉非尼治疗晚期转移性肾癌的安全性,探讨其不良反应的特点、预防及治疗方法。方法 2006年4月至2008年12月，我们对31例转移性肾癌患者行口服索拉非尼治疗，其中男20例，女11例；有17例患者为一线用药，14例为二线用药。25例行原发肿瘤切除，除1例为肾乳头状细胞癌外，其余均为透明细胞癌(2例含肉瘤成分)，6例患者无法行手术切除，但经穿刺活检证实为肾透明细胞癌。治疗方案：索拉非尼400mg，2次/日；2例患者接受索拉非尼增量治疗，每次口服600mg，2次/日；1例同时使用免疫治疗。结果本组31例患者出现的不良反应包括消化系统反应22例(71.0%)、手足综合征17例(54.8%)、疲乏13例(42.0%)、高血压7例(22.6%)、肝功能损害3例(9.7%)，其中3级不良反应4例(12.9%)，无4级不良反应，给予对症处理、减量或停药后均缓解。结论索拉非尼治疗转移性肾癌有较多的不良反应，但多数较为轻微，经积极适当的处理，绝大多数患者可耐受,安全性较好。

Abstract: Objective To evaluate the safety ofChinese patients withmetastatic renal cell carcinoma (mRCC)treatedby Soratenib, investigate the toxicities and discuss the management. Methods From Apr2006 to Dec2008, wetreated 31 patients of mRCC with Sorafenib. All of the patients received Sorafenib 400mg, twice daily, continuous intake, twoof themreceived dose enlargement from 800mg/d to 1200mg/d, oneof them combined with immunotherapy. Results The most frequently occurring drug-related adverse events (any grade) were gastrointestinal symptom 22(71.0%), hand-foot syndrome 17(54.8%), fatigue 13(42.0%), hypertension 7(22.6%), dysfunction of liver 3(9.7%), only 4(12.9%) patients had serious drug related adverse events. Conclusion Although there was much drug related adverse events due to Sorafenib, most patients had good tolerance to it with reasonable measure and treatment to prevent and treat adverse events.

HTML全文

参考文献(0)

施引文献

资源附件(0)